|
Boswellia serrata Extract
DEFINITION
Boswellia serrata Extract is prepared from pulverized Boswellia serrata, using suitable solvents such as isopropanol, alcohol, methanol, hexanes, or mixtures of these solvents. The ratio of starting plant material to Extract is approximately 6:1. It contains NLT 90.0% and NMT 110.0% of the labeled amount of Extract, calculated, on the dried basis, as the sum of 11-keto-
IDENTIFICATION
• A. Thin-Layer Chromatographic Identification Test
Standard solution:
Treat a quantity of USP Boswellia serrata Extract RS with gentle heating in methanol to obtain a solution having a known concentration of 30 mg/mL, cool, centrifuge, and use the supernatant.
Sample solution:
Treat a quantity of Extract with gentle heating in methanol to obtain a solution having a known concentration of 30 mg/mL, cool, centrifuge, and use the supernatant.
Adsorbent:
0.25-mm layer of chromatographic silica gel
Developing solvent system:
A mixture of hexane and ethyl acetate (6:4)
Dipping reagent:
Prepare a solution of 10% sulfuric acid in methanol. [NotePrepare fresh immediately before use. ]
Application volume:
10 µL
Analysis
Samples:
Standard solution and Sample solution
Apply the Samples as bands to a suitable thin-layer chromatographic plate (see Chromatography
Acceptance criteria:
Under UV light at 254 nm, the Sample solution exhibits two main zones due to 11-keto-
• B.
The 210-nm chromatogram of the Sample solution, in the test for Content of Keto-Derivatives of
COMPOSITION
• Content of Keto-Derivatives of
Standard solution A:
Dissolve a quantity of USP 3-Acetyl-11-keto-
Standard solution B:
Treat a quantity of USP Boswellia serrata Extract RS with gentle heating in methanol to obtain a solution having a known concentration of 10 mg/mL. Before injection, pass through a filter of 0.45-µm pore size.
Sample solution:
Treat a quantity of Extract with gentle heating in methanol to obtain a solution having a known concentration of 10 mg/mL. Before injection, pass through a filter of 0.45-µm pore size, and discard the first few mL of the filtrate.
Mobile phase:
Prepare a filtered and degassed mixture of acetonitrile, water, and glacial acetic acid (900:100:0.1). Make adjustments if necessary.
Chromatographic system
Mode:
LC
Detector:
UV 254 nm
Column:
4.6-mm × 25-cm; packing L1
Flow rate:
See the gradient table below.
Injection size:
20 µL
System suitability
Samples:
Standard solution A and Standard solution B
[NoteThe relative retention times for 11-keto-
Suitability requirements:
The chromatogram of Standard solution B is similar to the 254-nm Reference Chromatogram provided with the USP Boswellia serrata Extract RS.
Tailing factor:
NMT 1.5, 11-keto-
Relative standard deviation:
NMT 2.0% of the 3-acetyl-11-keto-
Analysis
Samples:
Standard solution A, Standard solution B, and Sample solution
Using the chromatogram of Standard solution B and the 254-nm Reference Chromatogram provided with the lot of USP Boswellia serrata Extract RS, identify the retention times of the peaks of 11-keto-
Separately calculate the percentages of 11-keto-
Result = (rU/rS) × (CSV/W) × 100F
Acceptance criteria:
Add the percentages of the two analytes. It contains NLT 90.0% and NMT 110.0% of the labeled amount of Extract, calculated on the dried basis, as the sum of 11-keto-
IMPURITIES
Inorganic Impurities
• Heavy Metals, Method II
Organic Impurities
• Procedure: Articles of Botanical Origin, General Method for Pesticide Residues Analysis
SPECIFIC TESTS
• Loss on Drying
• Microbial Enumeration Tests
• Microbiological Procedures for Absence of Specified Microorganisms
ADDITIONAL REQUIREMENTS
• Packaging and Storage:
Preserve in well-closed containers, protected from light and moisture, and store in a cool place.
• Labeling:
The label states the Latin binomial and, following the official name, the part of the plant from which the article was prepared. It meets other labeling requirements under Botanical Extracts
• USP Reference Standards
USP Boswellia serrata Extract RS
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 1215
Pharmacopeial Forum: Volume No. 35(4) Page 891
|